STRIDER NZAus: a multicentre randomised controlled trial of sildenafil therapy in early-onset fetal growth restriction
- PMID: 30779295
- DOI: 10.1111/1471-0528.15658
STRIDER NZAus: a multicentre randomised controlled trial of sildenafil therapy in early-onset fetal growth restriction
Abstract
Objective: To assess the effect of maternal sildenafil therapy on fetal growth in pregnancies with early-onset fetal growth restriction.
Design: A randomised placebo-controlled trial.
Setting: Thirteen maternal-fetal medicine units across New Zealand and Australia.
Population: Women with singleton pregnancies affected by fetal growth restriction at 22+0 to 29+6 weeks.
Methods: Women were randomised to oral administration of 25 mg sildenafil citrate or visually matching placebo three times daily until 32+0 weeks, birth or fetal death (whichever occurred first).
Main outcome measures: The primary outcome was the proportion of pregnancies with an increase in fetal growth velocity. Secondary outcomes included live birth, survival to hospital discharge free of major neonatal morbidity and pre-eclampsia.
Results: Sildenafil did not affect the proportion of pregnancies with an increase in fetal growth velocity; 32/61 (52.5%) sildenafil-treated, 39/57 (68.4%) placebo-treated [adjusted odds ratio (OR) 0.49, 95% CI 0.23-1.05] and had no effect on abdominal circumference Z-scores (P = 0.61). Sildenafil use was associated with a lower mean uterine artery pulsatility index after 48 hours of treatment (1.56 versus 1.81; P = 0.02). The live birth rate was 56/63 (88.9%) for sildenafil-treated and 47/59 (79.7%) for placebo-treated (adjusted OR 2.50, 95% CI 0.80-7.79); survival to hospital discharge free of major neonatal morbidity was 42/63 (66.7%) for sildenafil-treated and 33/59 (55.9%) for placebo-treated (adjusted OR 1.93, 95% CI 0.84-4.45); and new-onset pre-eclampsia was 9/51 (17.7%) for sildenafil-treated and 14/55 (25.5%) for placebo-treated (OR 0.67, 95% CI 0.26-1.75).
Conclusions: Maternal sildenafil use had no effect on fetal growth velocity. Prospectively planned meta-analyses will determine whether sildenafil exerts other effects on maternal and fetal/neonatal wellbeing.
Tweetable abstract: Maternal sildenafil use has no beneficial effect on growth in early-onset FGR, but also no evidence of harm.
Keywords: Fetal growth restriction; intrauterine growth restriction; pre-eclampsia; sildenafil; small for gestational age; uterine artery Doppler.
© 2019 Royal College of Obstetricians and Gynaecologists.
Comment in
-
Sildenafil therapy in early-onset fetal growth restriction: waiting for the individual patient data meta-analysis.BJOG. 2019 Jul;126(8):1007. doi: 10.1111/1471-0528.15753. Epub 2019 Apr 24. BJOG. 2019. PMID: 30957410 No abstract available.
Similar articles
-
Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial.Lancet Child Adolesc Health. 2018 Feb;2(2):93-102. doi: 10.1016/S2352-4642(17)30173-6. Epub 2017 Dec 7. Lancet Child Adolesc Health. 2018. PMID: 30169244 Clinical Trial.
-
STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): an international consortium of randomised placebo-controlled trials.BMC Pregnancy Childbirth. 2017 Dec 28;17(1):440. doi: 10.1186/s12884-017-1594-z. BMC Pregnancy Childbirth. 2017. PMID: 29282009 Free PMC article. Clinical Trial.
-
Detailed statistical analysis plan for the Dutch STRIDER (Sildenafil TheRapy In Dismal prognosis Early-onset fetal growth Restriction) randomised clinical trial on sildenafil versus placebo for pregnant women with severe early onset fetal growth restriction.Trials. 2019 Jan 11;20(1):42. doi: 10.1186/s13063-018-3136-z. Trials. 2019. PMID: 30635020 Free PMC article.
-
Effect of L-arginine and sildenafil citrate on intrauterine growth restriction fetuses: a meta-analysis.BMC Pregnancy Childbirth. 2016 Aug 16;16:225. doi: 10.1186/s12884-016-1009-6. BMC Pregnancy Childbirth. 2016. PMID: 27528012 Free PMC article. Review.
-
The efficacy of sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction: the STRIDER RCT.Southampton (UK): National Institute for Health and Care Research; 2024 Oct. Southampton (UK): National Institute for Health and Care Research; 2024 Oct. PMID: 39591485 Free Books & Documents. Review.
Cited by
-
Safety and efficacy of phosphodiesterase-5 (PDE-5) inhibitors in fetal growth restriction: a systematic literature review and meta-analysis.J Pharm Pharm Sci. 2024 Aug 15;27:13206. doi: 10.3389/jpps.2024.13206. eCollection 2024. J Pharm Pharm Sci. 2024. PMID: 39211421 Free PMC article.
-
Placental Ischemia Says "NO" to Proper NOS-Mediated Control of Vascular Tone and Blood Pressure in Preeclampsia.Int J Mol Sci. 2021 Oct 19;22(20):11261. doi: 10.3390/ijms222011261. Int J Mol Sci. 2021. PMID: 34681920 Free PMC article. Review.
-
Potency of Tokishakuyakusan in treating preeclampsia: Drug repositioning method by in vitro screening of the Kampo library.PLoS One. 2020 Dec 30;15(12):e0244684. doi: 10.1371/journal.pone.0244684. eCollection 2020. PLoS One. 2020. PMID: 33378412 Free PMC article.
-
Maternal tadalafil treatment does not increase uterine artery blood flow or oxygen delivery in the pregnant ewe.Exp Physiol. 2024 Jun;109(6):980-991. doi: 10.1113/EP091593. Epub 2024 Apr 12. Exp Physiol. 2024. PMID: 38606906 Free PMC article.
-
Animal models of preeclampsia: investigating pathophysiology and therapeutic targets.Am J Obstet Gynecol. 2022 Feb;226(2S):S973-S987. doi: 10.1016/j.ajog.2020.10.025. Epub 2021 Mar 12. Am J Obstet Gynecol. 2022. PMID: 33722383 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous